Skip to content

Released Aug 5, 2025, before the open

10-Q filed Aug 5, 2025, 36 days after period end · 0001493152-25-011588

Q2 2025 · 10-Q
Revenue$622.85K+595.4% vs Q2 2024+563.6% vs Q1 2025
Net Income-$2.21MN/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.41N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$2,404,353N/M
Operating Cash Flowderived-$1,886,234N/M
Margins · derived
Operating margin-386.0%+3290.2 pt vs Q2 2024
Net margin-354.1%+3072.0 pt vs Q2 2024

What the release said

The release

Same quarter

MetricQ2 2025Q2 2024Q2 2023Q2 2022
Revenue$622.85K$89.57K$0.00$500.00K
Net Income-$2.21M-$3.07M-$3.55M-$2.63M
EPS Diluted-$0.41-$0.56-$0.68-$0.61

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Lipocine Inc. · CIK 1535955 · Engraved from SEC EDGAR